A Randomized, Double-Blind Study of the Efficacy of Fleroxacin versus Trimethoprim-Sulfamethoxazole in Men with Culture-Proven Chancroid
Identifieur interne : 001917 ( Istex/Corpus ); précédent : 001916; suivant : 001918A Randomized, Double-Blind Study of the Efficacy of Fleroxacin versus Trimethoprim-Sulfamethoxazole in Men with Culture-Proven Chancroid
Auteurs : Pierre J. Plourde ; Lourdes J. D'Costa ; Elizabeth Agoki ; John Ombette ; Jackoniah O. Ndinya-Achola ; Leslie A. Slaney ; Allan R. Ronald ; Francis A. PlummerSource :
- Journal of Infectious Diseases [ 0022-1899 ] ; 1992-05.
Abstract
Chancroid is linked to the spread of human immunodeficiency virus type 1 (HIV-1) in East Africa. Effective, easily administered therapy is a priority for the control of Haemophilus ducreyi. The efficacy of a single oral dose of fleroxacin, 400 mg, was compared to a 3-day oral course of trimethoprim-sulfamethoxazole (TMP-SMZ), 160/800 mg, twice daily for the treatment of chancroid in 98 HIV-l-seronegative men in Nairobi, Kenya. No differences were noted between the two groups with respect to demographic characteristics, sexual behavior, and clinical characteristics. Culture-proven failure occurred in 1 (3%) of 36 fleroxacin-treated patients and in 11 (30%) of 37 TMP-SMZ-treated patients (P = .005). Fleroxacin, as a single oral dose, is an effective treatment for culture-proven chancroid in patients who are HIV-1 seronegative. TMP-SMZ is no longer predictably effectivedue to the recent emergence of resistance to both sulfonamides and to trimethoprim.
Url:
DOI: 10.1093/infdis/165.5.949
Links to Exploration step
ISTEX:4CD986E48FF9497B3D0272FD427A56991DABC6A8Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>A Randomized, Double-Blind Study of the Efficacy of Fleroxacin versus Trimethoprim-Sulfamethoxazole in Men with Culture-Proven Chancroid</title><author><name sortKey="Plourde, Pierre J" sort="Plourde, Pierre J" uniqKey="Plourde P" first="Pierre J." last="Plourde">Pierre J. Plourde</name><affiliation><mods:affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="D Costa, Lourdes J" sort="D Costa, Lourdes J" uniqKey="D Costa L" first="Lourdes J." last="D'Costa">Lourdes J. D'Costa</name><affiliation><mods:affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Agoki, Elizabeth" sort="Agoki, Elizabeth" uniqKey="Agoki E" first="Elizabeth" last="Agoki">Elizabeth Agoki</name><affiliation><mods:affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Ombette, John" sort="Ombette, John" uniqKey="Ombette J" first="John" last="Ombette">John Ombette</name><affiliation><mods:affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Ndinya Achola, Jackoniah O" sort="Ndinya Achola, Jackoniah O" uniqKey="Ndinya Achola J" first="Jackoniah O." last="Ndinya-Achola">Jackoniah O. Ndinya-Achola</name><affiliation><mods:affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Slaney, Leslie A" sort="Slaney, Leslie A" uniqKey="Slaney L" first="Leslie A." last="Slaney">Leslie A. Slaney</name><affiliation><mods:affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Ronald, Allan R" sort="Ronald, Allan R" uniqKey="Ronald A" first="Allan R." last="Ronald">Allan R. Ronald</name><affiliation><mods:affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Plummer, Francis A" sort="Plummer, Francis A" uniqKey="Plummer F" first="Francis A." last="Plummer">Francis A. Plummer</name><affiliation><mods:affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4CD986E48FF9497B3D0272FD427A56991DABC6A8</idno><date when="1992" year="1992">1992</date><idno type="doi">10.1093/infdis/165.5.949</idno><idno type="url">https://api.istex.fr/document/4CD986E48FF9497B3D0272FD427A56991DABC6A8/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001917</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001917</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">A Randomized, Double-Blind Study of the Efficacy of Fleroxacin versus Trimethoprim-Sulfamethoxazole in Men with Culture-Proven Chancroid</title><author><name sortKey="Plourde, Pierre J" sort="Plourde, Pierre J" uniqKey="Plourde P" first="Pierre J." last="Plourde">Pierre J. Plourde</name><affiliation><mods:affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="D Costa, Lourdes J" sort="D Costa, Lourdes J" uniqKey="D Costa L" first="Lourdes J." last="D'Costa">Lourdes J. D'Costa</name><affiliation><mods:affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Agoki, Elizabeth" sort="Agoki, Elizabeth" uniqKey="Agoki E" first="Elizabeth" last="Agoki">Elizabeth Agoki</name><affiliation><mods:affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Ombette, John" sort="Ombette, John" uniqKey="Ombette J" first="John" last="Ombette">John Ombette</name><affiliation><mods:affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Ndinya Achola, Jackoniah O" sort="Ndinya Achola, Jackoniah O" uniqKey="Ndinya Achola J" first="Jackoniah O." last="Ndinya-Achola">Jackoniah O. Ndinya-Achola</name><affiliation><mods:affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Slaney, Leslie A" sort="Slaney, Leslie A" uniqKey="Slaney L" first="Leslie A." last="Slaney">Leslie A. Slaney</name><affiliation><mods:affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Ronald, Allan R" sort="Ronald, Allan R" uniqKey="Ronald A" first="Allan R." last="Ronald">Allan R. Ronald</name><affiliation><mods:affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</mods:affiliation></affiliation></author><author><name sortKey="Plummer, Francis A" sort="Plummer, Francis A" uniqKey="Plummer F" first="Francis A." last="Plummer">Francis A. Plummer</name><affiliation><mods:affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Infectious Diseases</title><title level="j" type="abbrev">J Infect Dis.</title><idno type="ISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><publisher>The University of Chicago Press</publisher><date type="published" when="1992-05">1992-05</date><biblScope unit="volume">165</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="949">949</biblScope><biblScope unit="page" to="952">952</biblScope></imprint><idno type="ISSN">0022-1899</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-1899</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Chancroid is linked to the spread of human immunodeficiency virus type 1 (HIV-1) in East Africa. Effective, easily administered therapy is a priority for the control of Haemophilus ducreyi. The efficacy of a single oral dose of fleroxacin, 400 mg, was compared to a 3-day oral course of trimethoprim-sulfamethoxazole (TMP-SMZ), 160/800 mg, twice daily for the treatment of chancroid in 98 HIV-l-seronegative men in Nairobi, Kenya. No differences were noted between the two groups with respect to demographic characteristics, sexual behavior, and clinical characteristics. Culture-proven failure occurred in 1 (3%) of 36 fleroxacin-treated patients and in 11 (30%) of 37 TMP-SMZ-treated patients (P = .005). Fleroxacin, as a single oral dose, is an effective treatment for culture-proven chancroid in patients who are HIV-1 seronegative. TMP-SMZ is no longer predictably effectivedue to the recent emergence of resistance to both sulfonamides and to trimethoprim.</div></front></TEI><istex><corpusName>oup</corpusName><author><json:item><name>Pierre J. Plourde</name><affiliations><json:string>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</json:string></affiliations></json:item><json:item><name>Lourdes J. D'Costa</name><affiliations><json:string>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</json:string></affiliations></json:item><json:item><name>Elizabeth Agoki</name><affiliations><json:string>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</json:string></affiliations></json:item><json:item><name>John Ombette</name><affiliations><json:string>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</json:string></affiliations></json:item><json:item><name>Jackoniah O. Ndinya-Achola</name><affiliations><json:string>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</json:string></affiliations></json:item><json:item><name>Leslie A. Slaney</name><affiliations><json:string>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</json:string></affiliations></json:item><json:item><name>Allan R. Ronald</name><affiliations><json:string>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</json:string></affiliations></json:item><json:item><name>Francis A. Plummer</name><affiliations><json:string>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</json:string></affiliations></json:item></author><language><json:string>unknown</json:string></language><originalGenre><json:string>research-article</json:string></originalGenre><abstract>Chancroid is linked to the spread of human immunodeficiency virus type 1 (HIV-1) in East Africa. Effective, easily administered therapy is a priority for the control of Haemophilus ducreyi. The efficacy of a single oral dose of fleroxacin, 400 mg, was compared to a 3-day oral course of trimethoprim-sulfamethoxazole (TMP-SMZ), 160/800 mg, twice daily for the treatment of chancroid in 98 HIV-l-seronegative men in Nairobi, Kenya. No differences were noted between the two groups with respect to demographic characteristics, sexual behavior, and clinical characteristics. Culture-proven failure occurred in 1 (3%) of 36 fleroxacin-treated patients and in 11 (30%) of 37 TMP-SMZ-treated patients (P = .005). Fleroxacin, as a single oral dose, is an effective treatment for culture-proven chancroid in patients who are HIV-1 seronegative. TMP-SMZ is no longer predictably effectivedue to the recent emergence of resistance to both sulfonamides and to trimethoprim.</abstract><qualityIndicators><score>6.52</score><pdfWordCount>2816</pdfWordCount><pdfCharCount>17948</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>4</pdfPageCount><pdfPageSize>581.16 x 771 pts</pdfPageSize><refBibsNative>false</refBibsNative><abstractWordCount>142</abstractWordCount><abstractCharCount>962</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>A Randomized, Double-Blind Study of the Efficacy of Fleroxacin versus Trimethoprim-Sulfamethoxazole in Men with Culture-Proven Chancroid</title><genre><json:string>research-article</json:string></genre><host><title>Journal of Infectious Diseases</title><language><json:string>unknown</json:string></language><issn><json:string>0022-1899</json:string></issn><eissn><json:string>1537-6613</json:string></eissn><publisherId><json:string>jid</json:string></publisherId><volume>165</volume><issue>5</issue><pages><first>949</first><last>952</last></pages><genre><json:string>journal</json:string></genre></host><categories><wos><json:string>science</json:string><json:string>microbiology</json:string><json:string>infectious diseases</json:string><json:string>immunology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>biomedical research</json:string><json:string>microbiology</json:string></scienceMetrix></categories><publicationDate>1992</publicationDate><copyrightDate>1992</copyrightDate><doi><json:string>10.1093/infdis/165.5.949</json:string></doi><id>4CD986E48FF9497B3D0272FD427A56991DABC6A8</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/4CD986E48FF9497B3D0272FD427A56991DABC6A8/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/4CD986E48FF9497B3D0272FD427A56991DABC6A8/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/4CD986E48FF9497B3D0272FD427A56991DABC6A8/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">A Randomized, Double-Blind Study of the Efficacy of Fleroxacin versus Trimethoprim-Sulfamethoxazole in Men with Culture-Proven Chancroid</title><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://publisher-list.data.istex.fr">The University of Chicago Press</publisher><availability><licence><p>© 1992 by The University of Chicago</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-GTWS0RDP-M">oup</p></availability><date>1992</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note>Reprints or correspondence: Dr. Pierre J. Plourde, Department of Medical Microbiology, Basic Sciences Bldg., Rm. 544,730 William Ave., Winnipeg, Manitoba, Canada R3E OW3.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">A Randomized, Double-Blind Study of the Efficacy of Fleroxacin versus Trimethoprim-Sulfamethoxazole in Men with Culture-Proven Chancroid</title><author xml:id="author-0000" corresp="yes"><persName><forename type="first">Pierre J.</forename><surname>Plourde</surname></persName><affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Lourdes J.</forename><surname>D'Costa</surname></persName><affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Elizabeth</forename><surname>Agoki</surname></persName><affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</affiliation></author><author xml:id="author-0003"><persName><forename type="first">John</forename><surname>Ombette</surname></persName><affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Jackoniah O.</forename><surname>Ndinya-Achola</surname></persName><affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</affiliation></author><author xml:id="author-0005"><persName><forename type="first">Leslie A.</forename><surname>Slaney</surname></persName><affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</affiliation></author><author xml:id="author-0006"><persName><forename type="first">Allan R.</forename><surname>Ronald</surname></persName><affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</affiliation></author><author xml:id="author-0007"><persName><forename type="first">Francis A.</forename><surname>Plummer</surname></persName><affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</affiliation></author><idno type="istex">4CD986E48FF9497B3D0272FD427A56991DABC6A8</idno><idno type="ark">ark:/67375/HXZ-03WZMM43-6</idno><idno type="DOI">10.1093/infdis/165.5.949</idno></analytic><monogr><title level="j">Journal of Infectious Diseases</title><title level="j" type="abbrev">J Infect Dis.</title><idno type="pISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><idno type="publisher-id">jid</idno><idno type="PublisherID-hwp">jinfdis</idno><imprint><publisher>The University of Chicago Press</publisher><date type="published" when="1992-05"></date><biblScope unit="volume">165</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="949">949</biblScope><biblScope unit="page" to="952">952</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1992</date></creation><abstract><p>Chancroid is linked to the spread of human immunodeficiency virus type 1 (HIV-1) in East Africa. Effective, easily administered therapy is a priority for the control of Haemophilus ducreyi. The efficacy of a single oral dose of fleroxacin, 400 mg, was compared to a 3-day oral course of trimethoprim-sulfamethoxazole (TMP-SMZ), 160/800 mg, twice daily for the treatment of chancroid in 98 HIV-l-seronegative men in Nairobi, Kenya. No differences were noted between the two groups with respect to demographic characteristics, sexual behavior, and clinical characteristics. Culture-proven failure occurred in 1 (3%) of 36 fleroxacin-treated patients and in 11 (30%) of 37 TMP-SMZ-treated patients (P = .005). Fleroxacin, as a single oral dose, is an effective treatment for culture-proven chancroid in patients who are HIV-1 seronegative. TMP-SMZ is no longer predictably effectivedue to the recent emergence of resistance to both sulfonamides and to trimethoprim.</p></abstract></profileDesc><revisionDesc><change when="1992-05">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2017-10-6">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/4CD986E48FF9497B3D0272FD427A56991DABC6A8/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus oup, element #text not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="hwp">jinfdis</journal-id>
<journal-id journal-id-type="publisher-id">jid</journal-id>
<journal-title>Journal of Infectious Diseases</journal-title>
<abbrev-journal-title>J Infect Dis.</abbrev-journal-title>
<issn pub-type="ppub">0022-1899</issn>
<issn pub-type="epub">1537-6613</issn>
<publisher><publisher-name>The University of Chicago Press</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1093/infdis/165.5.949</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Concise Communications</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A Randomized, Double-Blind Study of the Efficacy of Fleroxacin versus Trimethoprim-Sulfamethoxazole in Men with Culture-Proven Chancroid</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Plourde</surname><given-names>Pierre J.</given-names>
</name><xref ref-type="corresp"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>D'Costa</surname><given-names>Lourdes J.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Agoki</surname><given-names>Elizabeth</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ombette</surname><given-names>John</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ndinya-Achola</surname><given-names>Jackoniah O.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Slaney</surname><given-names>Leslie A.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ronald</surname><given-names>Allan R.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Plummer</surname><given-names>Francis A.</given-names>
</name>
</contrib>
<aff><institution>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,</institution>, <addr-line>Nairobi, Kenya</addr-line></aff>
<aff><institution>Departments of Internal Medicine and Medical Microbiology, University of Manitoba</institution>, <addr-line>Winnipeg, Canada</addr-line></aff>
</contrib-group>
<author-notes>
<corresp id="cor">Reprints or correspondence: Dr. Pierre J. Plourde, Department of Medical Microbiology, Basic Sciences Bldg., Rm. 544,730 William Ave., Winnipeg, Manitoba, Canada R3E OW3.</corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>5</month>
<year>1992</year>
</pub-date>
<volume>165</volume>
<issue>5</issue>
<fpage>949</fpage>
<lpage>952</lpage>
<history>
<date date-type="received">
<day>17</day>
<month>9</month>
<year>1991</year>
</date>
<date date-type="rev-recd">
<day>13</day>
<month>1</month>
<year>1992</year>
</date>
</history>
<copyright-statement>© 1992 by The University of Chicago</copyright-statement>
<copyright-year>1992</copyright-year>
<abstract>
<p>Chancroid is linked to the spread of human immunodeficiency virus type 1 (HIV-1) in East Africa. Effective, easily administered therapy is a priority for the control of <italic>Haemophilus ducreyi</italic>. The efficacy of a single oral dose of fleroxacin, 400 mg, was compared to a 3-day oral course of trimethoprim-sulfamethoxazole (TMP-SMZ), 160/800 mg, twice daily for the treatment of chancroid in 98 HIV-l-seronegative men in Nairobi, Kenya. No differences were noted between the two groups with respect to demographic characteristics, sexual behavior, and clinical characteristics. Culture-proven failure occurred in 1 (3%) of 36 fleroxacin-treated patients and in 11 (30%) of 37 TMP-SMZ-treated patients (<italic>P</italic> = .005). Fleroxacin, as a single oral dose, is an effective treatment for culture-proven chancroid in patients who are HIV-1 seronegative. TMP-SMZ is no longer predictably effectivedue to the recent emergence of resistance to both sulfonamides and to trimethoprim.</p>
</abstract>
</article-meta>
</front>
</article>
</istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>A Randomized, Double-Blind Study of the Efficacy of Fleroxacin versus Trimethoprim-Sulfamethoxazole in Men with Culture-Proven Chancroid</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>A Randomized, Double-Blind Study of the Efficacy of Fleroxacin versus Trimethoprim-Sulfamethoxazole in Men with Culture-Proven Chancroid</title></titleInfo><name type="personal" displayLabel="corresp"><namePart type="given">Pierre J.</namePart><namePart type="family">Plourde</namePart><affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Lourdes J.</namePart><namePart type="family">D'Costa</namePart><affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Elizabeth</namePart><namePart type="family">Agoki</namePart><affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">John</namePart><namePart type="family">Ombette</namePart><affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jackoniah O.</namePart><namePart type="family">Ndinya-Achola</namePart><affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Leslie A.</namePart><namePart type="family">Slaney</namePart><affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Allan R.</namePart><namePart type="family">Ronald</namePart><affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Francis A.</namePart><namePart type="family">Plummer</namePart><affiliation>World Health Organisation Centre for Research and Training on Sexually Transmitted Diseases, Department of Medical Microbiology, University of Nairobi, and Special Treatment Clinic Nairobi City Commission,, Nairobi, Kenya, Winnipeg, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>The University of Chicago Press</publisher><dateIssued encoding="w3cdtf">1992-05</dateIssued><copyrightDate encoding="w3cdtf">1992</copyrightDate></originInfo><abstract>Chancroid is linked to the spread of human immunodeficiency virus type 1 (HIV-1) in East Africa. Effective, easily administered therapy is a priority for the control of Haemophilus ducreyi. The efficacy of a single oral dose of fleroxacin, 400 mg, was compared to a 3-day oral course of trimethoprim-sulfamethoxazole (TMP-SMZ), 160/800 mg, twice daily for the treatment of chancroid in 98 HIV-l-seronegative men in Nairobi, Kenya. No differences were noted between the two groups with respect to demographic characteristics, sexual behavior, and clinical characteristics. Culture-proven failure occurred in 1 (3%) of 36 fleroxacin-treated patients and in 11 (30%) of 37 TMP-SMZ-treated patients (P = .005). Fleroxacin, as a single oral dose, is an effective treatment for culture-proven chancroid in patients who are HIV-1 seronegative. TMP-SMZ is no longer predictably effectivedue to the recent emergence of resistance to both sulfonamides and to trimethoprim.</abstract><note type="author-notes">Reprints or correspondence: Dr. Pierre J. Plourde, Department of Medical Microbiology, Basic Sciences Bldg., Rm. 544,730 William Ave., Winnipeg, Manitoba, Canada R3E OW3.</note><relatedItem type="host"><titleInfo><title>Journal of Infectious Diseases</title></titleInfo><titleInfo type="abbreviated"><title>J Infect Dis.</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0022-1899</identifier><identifier type="eISSN">1537-6613</identifier><identifier type="PublisherID">jid</identifier><identifier type="PublisherID-hwp">jinfdis</identifier><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>165</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>949</start><end>952</end></extent></part></relatedItem><identifier type="istex">4CD986E48FF9497B3D0272FD427A56991DABC6A8</identifier><identifier type="DOI">10.1093/infdis/165.5.949</identifier><accessCondition type="use and reproduction" contentType="copyright">© 1992 by The University of Chicago</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-GTWS0RDP-M">oup</recordContentSource><recordOrigin>© 1992 by The University of Chicago</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/document/4CD986E48FF9497B3D0272FD427A56991DABC6A8/metadata/json</uri></json:item></metadata><covers><json:item><extension>tiff</extension><original>true</original><mimetype>image/tiff</mimetype><uri>https://api.istex.fr/document/4CD986E48FF9497B3D0272FD427A56991DABC6A8/covers/tiff</uri></json:item></covers><annexes><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/4CD986E48FF9497B3D0272FD427A56991DABC6A8/annexes/pdf</uri></json:item></annexes><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001917 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001917 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:4CD986E48FF9497B3D0272FD427A56991DABC6A8
|texte= A Randomized, Double-Blind Study of the Efficacy of Fleroxacin versus Trimethoprim-Sulfamethoxazole in Men with Culture-Proven Chancroid
}}
| This area was generated with Dilib version V0.6.32. |  |